Possible pathogenic link between migraine and urotensin-II

Journal of Child Neurology

Volumn 23, Issue 11, 2008, Pages 1249-1253

  Bicak, Ugur ^a   Karabiber, Hamza ^c,d   Ozerol, Halil I ^a,b,c   Aslan, Mehmet ^a   Ilhan, Atilla ^c   Yakinci, Cengiz ^a  

^a INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b KSU Medical School   (Turkey)

^c FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

^d KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

Etiopathogenesis; Migraine; Urotensin II

Indexed keywords

UROTENSIN II;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MALE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; STRESS;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; UROTENSINS; YOUNG ADULT;

EID: 54549127456     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808318052     Document Type: Article

References (26)

1. Mack KJ Episodic and chronic migraine in children. Semin Neurol. 2006;26:223-231.
2. Mascia A., Afra J., Schoenen J. Dopamine and migraine: A review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia. 1998;18:174-182.
3. Gotoh F., Komatsumoto S., Araki N., Gomi S. Noradrenergic nervous activity in migraine. Arch Neurol. 1984;41:951-955.
4. Janig W. Relationship between pain and autonomic phenomena in headache and other pain conditions. Cephalalgia. 2003;23:43-48.
5. Sanchez del Rio M., Alvarez Linera J. Functional neuroimaging of headaches. Lancet Neurol. 2004;3:645-651.
6. Coulouarn Y., Jegou S., Tostivint H., et al. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursor. FEBS Lett. 1999;457:28-32.
7. Pearson D., Shively JE, Clark BR, et al. Urotensin II: A somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A. 1980;77:5021-5024.
8. Ong KL, Lam KS, Cheung BM Urotensin II: Its function in health and its role in disease. Cardiovasc Drugs Ther. 2005;19:65-75.
9. Carotenuto A., Grieco P., Novellino E., Rovero P. Urotensin-II receptor peptide agonists. Med Res Rev. 2004;24:577-588.
10. Watson A., May CN Urotensin II, a novel peptide in central and peripheral cardiovascular control. Peptides. 2004;25:1759-1766.
11. Gartlon JE, Ashmeade T., Duxon M., et al. Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain. Eur J Pharmacol. 2004;493:95-98.
12. Yoshimoto T., Matsushita M., Hirata Y. Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides. 2004;25:1775-1781.
13. Russell FD Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther. 2004; 103: 223-243.
14. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd ed. Cephalalgia. 2004;24(suppl1):S9-S160.
15. Pietrobon D., Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4:386-398.
16. Olesen J. Cerebral and extracranial circulatory disturbances in migraine: Pathophysiological implications. Cerebrovasc Brain Metab Rev. 1991;3:1-28.
17. Zhang AY, Chen YF, Zhang DX, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol. 2003;285:792-798.
18. Maguire JJ, Davenport AP Is urotensin-II the new endothelin? Br J Pharmacol. 2002;137:579-588.
19. Juhasz G., Zsombok T., Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106:461-470.
20. Welch KM Concepts of headache pathogenesis: Insights into mechanisms of chronicity and new drug targets. Neurol Sci. 2003;24(suppl2):S149-S153.
21. Martinez F., Castillo J., Pardo J., et al. Catecholamine levels in plasma and CSF in migraine. J Neurol Neurosurg Psychiatry. 1993;56:1119-1121.
22. Hsu LK, Crisp AH, Kalucy RS, et al. Early morning migraine. Nocturnal plasma levels of catecholamines, tryptophan, glucose, and free fatty acids and sleep encephalographs. Lancet. 1977;1:447-451.
23. Føg-Moller F., Genefke IK, Bryndum B. Changes in concentration of catecholamines in blood during spontaneous migraine attacks. In: Grene H, ed. Current Concepts in Migraine Research. New York: Raven Press; 1978:115-119.
24. Watson AM, Lambert GW, Smith KJ, May CN Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension. 2003;42:373-379.
25. Gartlon J., Parker F., Harrison DC, et al. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology. 2001;155:426-433.
26. Matsumoto Y., Abe M., Watanabe T., et al. Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents. Neurosci Lett. 2004;358:99-102.